An urgent care operator in Ohio is one of the 14 sites in a phase 3 clinical trial for a prospective Allergan product to treat patients with diabetic gastroparesis (DG), a condition that slows or stops the movement of food from the stomach to the small intestine. The trial, officially titled A 46-week, Double-blind, Placebo-controlled, Phase 3 Study With a 6-week Randomized-withdrawal Period to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic …
Read More